Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBER Study of venetoclax to reduce the HIV reservoir in adults on antiretroviral therapy
2024-518873-32-00Phase 2Authorised
- Sponsor
- Central Denmark Region
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in Human immunodeficiency virus infection type 1, sponsored by Central Denmark Region. Primary endpoints: Treatment-emergent adverse events grade 3 or higher related to study treatment and All other treatment-emergent adverse events. Planned start Oct 2022; status: authorised.
02
Drugs
venetoclax
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2024-518873-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518873-32-00.